CHANGES IN THE COAGULATION CASCADE IN PATIENTS WITH PROGRESSIVE (METABOLIC) LIVERDISEASE - TG-study

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 140 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Healthy controls (population A):
•- minimum age of 18-years old
•- decision making capacity;Patients (group B) (minimum of 18 years old) with cirrhosis, as diagnosed by a GE-specialist, due to one of the following chronic liver diseases: Primary Biliairy Sclerosis (PBS), Primary Sclerosis Cholangitis (PSC), Hepatitis B, Hepatitis C, Non-Alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liverdisease, Non-Alcoholic Steatosis Hepatitis (NASH), Haemochromatosis, Cryptogenic levercirrhosis.

•For both healthy controls (population A) as patients (population B):
•- proven congenital diseases concerning primary hemostasis (e.g. M. von Willebrand), defects in fibrinolysis, coagulation factor deficiencies (e.g. hemophilia A and B), vasculair defects which leed to higher bleeding risk (e.g. M. Rendu-Osler-Weber).
•Patients using medication interfering with primary hemostasis or coagulation. Coagulation factor deficiencies due to malignancies, sepsis or trauma.

发起方

Medisch Universitair Ziekenhuis Maastricht